Investigational New Drugs

, Volume 24, Issue 3, pp 249–253 | Cite as

An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma

  • J. T. HartmannEmail author
  • K. Oechsle
  • J. Huober
  • A. Jakob
  • M. Azemar
  • M. Horger
  • L. Kanz
  • C. Bokemeyer
Phase II Studies


Background: The number of effective cytotoxic agents for the treatment of patients with metastatic adult type soft tissue sarcoma (STS) is limited, when patients have failed anthracyline-based chemotherapy. The aim of this trial was to evaluate the efficacy of gemcitabine in this setting. Methods: Between August 2001 and March 2003 19 patients were eligible to enter. Gemcitabine was administered as a 30-minutes infusion at a dosage of 1 g/m2 on day 1, 8 and 15 every 4 weeks. All patients had progressive disease during (n = 12) or shortly after an anthracycline-based regimen (n = 3). Results: Four of 19 patients did not start study treatment because of fulminant progression. Fifteen patients with a median age 47 years (32–72) were assessable. All patients had received at least one prior treatment regimen (range, 1–6) for metastatic disease containing anthracyclines (n = 15) and ifosfamide (n = 11). To date, a total of 72+ cycles have been applied (median; 3, 1–28+). Seven patients (47%) had progressive disease after completion of two cycles at the first response assessment. One patient (6%) attained a partial remission, and 7 patients (47%) achieved disease stabilisations. One patient is still on treatment after more than 2.5 years. The calculated progression-free rate at 3 and 6 months was 46.7% (CI95%, 21.4–71.9) and 13.3% (CI95%, (0–30.5). 95% of the cycles have been applied without any dose modification or treatment delay. Conclusions: Considering response and progression-free rate as the primary endpoints for phase II trials in pretreated STS, gemcitabine has moderate efficacy.

Key Words

advanced soft tissue sarcoma gemcitabine second-line chemotherapy refractory disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Patel SR: Systemic chemotherapy, in Pollock RE (ed): Soft tissue sarcomas, Hamilton Ontario, Canada, 2002, pp 323–328Google Scholar
  2. 2.
    Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 65: 167–178, 2005CrossRefPubMedGoogle Scholar
  3. 3.
    Benjamin RS, Legha SS, Patel SR, Nicaise C: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 31(Suppl 2): S174–S179, 1993PubMedGoogle Scholar
  4. 4.
    Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5: 840–850, 1987PubMedGoogle Scholar
  5. 5.
    Lopez M, Vici P, Di Lauro L, Carpano S: Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 20: 1329–1334, 2002CrossRefPubMedGoogle Scholar
  6. 6.
    Lorigan PC, Verweij J, Papai Z, Rodenhuis S, le Cesne A, Leahy MG, Radford J, Hogendoorn PC, Van Glabbeke M, Kirkpatrick A, Nielsen OS: Randomised phase III trial of two investigational schedules of ifosfamide versus standard dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma (ASTS). Proc Am Soc Clin Oncol 21: 2002 (abstr. 1616)Google Scholar
  7. 7.
    Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, Steward W, Daugaard S, VanGlabbeke M, Kirkpatrick A, Tursz T: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78: 1634–1639, 1998PubMedGoogle Scholar
  8. 8.
    Cure H, Krakowski I, Adenis A, Tubiana N, Kerbrat P, Roche H, Chevallier B, Lentz MA, Fumoleau P, Chollet P: Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer 34: 422–423, 1998CrossRefPubMedGoogle Scholar
  9. 9.
    Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C: Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 23(2C): 1899–1901, 2003PubMedGoogle Scholar
  10. 10.
    Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann JT: An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 21: 481–486, 2003CrossRefPubMedGoogle Scholar
  11. 11.
    Balcerzak SP, Benedetti J, Weiss GR, Natale RB: A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 76: 2248–2252, 1995PubMedGoogle Scholar
  12. 12.
    Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity. J Clin Oncol 19: 1248–1255, 2001PubMedGoogle Scholar
  13. 13.
    Look KY, Sandler A, Blessing JA, Lucci JA III, Rose PG: Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92: 644–647, 2004CrossRefPubMedGoogle Scholar
  14. 14.
    Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45: 177–181, 2000CrossRefPubMedGoogle Scholar
  15. 15.
    Merimsky O, Meller I, Kollender Y, Inbar M: Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer 34: 1296–1297, 1998PubMedGoogle Scholar
  16. 16.
    Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer 94: 3225–3229, 2002CrossRefPubMedGoogle Scholar
  17. 17.
    Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH: Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97: 1969–1973, 2003CrossRefPubMedGoogle Scholar
  18. 18.
    Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19: 3483–3489, 2001PubMedGoogle Scholar
  19. 19.
    Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K: Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11: 325–329, 2000CrossRefPubMedGoogle Scholar
  20. 20.
    Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, Van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38: 556–559, 2002CrossRefPubMedGoogle Scholar
  21. 21.
    WHO: International classification of diseases, 10th edition (ICD-10), in WHO (ed): Geneva, 1996Google Scholar
  22. 22.
    Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143–151, 1982PubMedGoogle Scholar
  23. 23.
    Kaplan EL, Maier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958Google Scholar
  24. 24.
    Burton GV, Rankin C, Flaherty LE, Borden EC, Mills GM, Antman KH: Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 22: 820, 2003 (abstr. 3297)Google Scholar
  25. 25.
    Lopez-Pousa A, Buesa J, Casado A, Garcia del Muro J, Poveda A, Maurel J, Martin J, Balana C, Martinez J: Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS). J Clin Oncol 22: 14S, 2004 (abstr. 9033)Google Scholar
  26. 26.
    Buesa JM, Losa R, Fernandez A, Sierra M, Esteban E, Diaz A, Lopez-Pousa A, Fra J: Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 101: 2261–2269, 2004CrossRefPubMedGoogle Scholar
  27. 27.
    Morgan JA, George S, Desai J, Amand MS, Horton D, Wilkins E, Manola J, Demetri GD: Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS). J Clin Oncol 22: 14S, 2004 (abstr. 9009)Google Scholar
  28. 28.
    Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20: 2824–2831, 2002CrossRefPubMedGoogle Scholar
  29. 29.
    Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22: 1706–1712, 2004CrossRefPubMedGoogle Scholar
  30. 30.
    Pisters PW, Ballo MT, Bekele N, Thall PF, Feig BW, Lin P, Cormier JN, Benjamin RS, Patel SR: Phase I trial using toxicity severity weights for dose finding of gemcitabine combined with radiation therapy and subsequent surgery for patients with extremity and trunk soft tissue sarcomas. J Clin Oncol 22: 14S, 2004 (abstr. 9008)CrossRefGoogle Scholar
  31. 31.
    Van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38: 543–549, 2002CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2005

Authors and Affiliations

  • J. T. Hartmann
    • 1
    • 2
    Email author
  • K. Oechsle
    • 1
  • J. Huober
    • 3
  • A. Jakob
    • 4
  • M. Azemar
    • 5
  • M. Horger
    • 2
    • 6
  • L. Kanz
    • 1
  • C. Bokemeyer
    • 1
  1. 1.Department of Medical Oncology, Hematology, Immunology, Rheumatology, PneumologyEberhard-Karls-UniversityTuebingen
  2. 2.Interdisciplinary Sarcoma Center, South West German Cancer CenterEberhard-Karls-UniversityTuebingen
  3. 3.Department of Gynaecology and ObstreticsEberhard-Karls-UniversityTuebingen
  4. 4.KlinikumOffenburg
  5. 5.Klinik TumorbiologieFreiburg
  6. 6.Department of RadiologyEberhard-Karls-UniversityTuebingen

Personalised recommendations